Supernus reported third-quarter 2026 total revenues of $226.8 million, up 18% from a year earlier, and net earnings of $20.9 million, or $0.35 per diluted share, compared with a net loss of $45.1 million a year earlier. The company raised its full-year 2026 total revenue and GAAP operating earnings guidance, but the guidance will no longer apply if the Indivior merger closes as expected on November 2, 2026.
Q3 2026 net earnings were $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or $0.80 per share, in Q3 2025.
Total revenues were $226.8 million, up from $192.1 million; ONAPGO net sales rose to $17.1 million from $6.8 million.
2026 total revenue guidance was raised to $875 million to $900 million from $860 million to $890 million.
The Indivior merger is expected to close November 2, 2026; Supernus common stock is expected to trade under SUPN on November 3, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Supernus Pharmaceuticals, Inc.'s 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$718.95M
+8.6%
$-0.68
-151.5%
-5.4%
FY2024
$661.82M
+8.9%
$1.32
+6500.0%
11.2%
FY2023
$607.52M
-8.9%
$0.02
-98.1%
0.2%
FY2022
$667.24M
+15.1%
$1.04
+6.1%
9.1%
FY2021
$579.77M
+11.4%
$0.98
-58.5%
9.2%
Frequently asked questions
When is Supernus Pharmaceuticals's next earnings date?
Supernus Pharmaceuticals has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Supernus Pharmaceuticals earn last quarter?
For the quarter ended Sep 2026, Supernus Pharmaceuticals reported diluted EPS of $0.35 on revenue of $226.77M (+18.0%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.